Photo from wikipedia
Abdel-Rahman [1] analyzed the overall survival-rate and disease-free survival of T1-2 N1 breast cancer patients after mastectomy, who were adjuvantly treated with various modern chemotherapeutic drugs (anthracyclines, taxanes) in 3… Click to show full abstract
Abdel-Rahman [1] analyzed the overall survival-rate and disease-free survival of T1-2 N1 breast cancer patients after mastectomy, who were adjuvantly treated with various modern chemotherapeutic drugs (anthracyclines, taxanes) in 3 prospective phase III chemotherapy trials. His analysis suggested no potential benefits of an additional adjuvant postmastectomy radiotherapy (PMRT). The included trials were the BIG 02/98 [6], the BCIRG 001 [7] and the BCIRG005 [5] trials. The author concludes that in T1-2 N1 breast cancer patients who have received modern chemotherapy drugs PMRT does not provide any benefit for overall and disease-free survival. Prospective studies are necessary.
Journal Title: Strahlentherapie und Onkologie
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!